Grail launches CCGA program: to support the development of early detection of cancer
Liquid biopsy company Grail said last week that they are pushing an ambitious plan to comprehensively analyze circulating DNA from at least 10,000 people. This is the first detail that Grail has revealed on how to develop early detection of pan-cancerous cancer since its inception in January.
Grail launches CCGA program to analyze heterogeneity of ctDNA
Their goal is to create a circulating cell-free DNA atlas (CCGA) that describes and compares the heterogeneity or variability of ctDNA in healthy and cancer patients. The map will support Grail's test product development program, enabling it to accurately calibrate test products to identify patterns in healthy people that indicate the tumor is forming.
To create the CCGA, Grail is working with multiple academic centers to recruit a total of 10,000 subjects to analyze their blood samples using a comprehensive targeted panel and ultra-deep sequencing strategy. The company plans to track subjects for five years and analyze changes in their circulating DNA patterns and levels. In this study cohort, 7,000 subjects will be cancer patients and another 3,000 subjects will be healthy controls.
Jeff Huber, CEO of Grail, said the company's sequencing analysis method will cover hundreds of genes, an order of magnitude larger than what is currently used by other companies in the field, but he does not provide detailed information on which genomic regions are covered. Moreover, their sequencing depth is an order of magnitude deeper than other companies.
Huber said, "The main challenges of early detection of cancer are twofold: one is cancer heterogeneity. Given the heterogeneity and the fact that we want to detect cancer at its earliest stages, we must study the genome very extensively to find mutations. Where it happens and can be detected. The other is depth, our goal is to be able to detect some molecules in a blood sample that can indicate cancer at the earliest stage, so our sequencing depth is an order of magnitude deeper than other companies. A test sample can produce terabytes of data."
Currently, Grail existing partners include: Guardian Research and Education Network, Mayo Clinic Cancer Institute and Hartford Healthcare. The CCGA study will eventually include more than forty clinical trial sites.
medical protective suit with shoecover,medical protective suit without shoes cover,hazmat suit,hooded coverall without seal tape
Shandong Zhushi Pharmaceutical Group Co.,LTD , https://www.sdzs-medical.com